F-18 Peptide Labeling via Aluminum Chelation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for labeling peptides with F-18 for in-vivo imaging are complex, require specialized equipment and personnel, and involve tedious processes that are not suitable for clinical settings, necessitating a simpler and more rapid method that minimizes radiation exposure and equipment requirements.
Innovation Solution
The method involves binding F-18 to a metal and then chelating the F-18 metal complex with a ligand on the peptide, using metals like aluminum or other elements from group IIIA, which are stable and can be incorporated into peptides without affecting ligand-receptor binding interactions, allowing for prepackaged kits for clinical use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional F-18 labeling methods are used, then labeling can be achieved, but the process becomes complex and requires specialized equipment and personnel
Solution Approach 1:
The patent introduces a metal ion (Al-18F complex) as an intermediary to facilitate F-18 labeling of peptides. The metal ion acts as a mediator that enables labeling through a simplified chelation mechanism, eliminating the need for complex conventional labeling procedures and specialized equipment while maintaining high specific activity and stability.
2Productivity
If conventional F-18 labeling methods are used, then labeling can be achieved, but purification steps are required to separate unlabeled from labeled peptide
Solution Approach 1:
The patent employs a preliminary action by pre-forming the Al-18F complex before introducing it to the peptide. This pre-complexation step ensures that the F-18 is already bound to the metal ion in a stable configuration, allowing direct chelation to the peptide without requiring subsequent purification steps to separate unlabeled from labeled peptide, thereby eliminating time loss.
3Measurement precision
If high specific activity is achieved, then imaging quality improves, but the half-life of F-18 must be optimized for manufacturing and distribution
Solution Approach 1:
The patent utilizes parameter changes by optimizing the chelation kinetics and stability constants of the Al-18F-peptide complex. By adjusting parameters such as pH, temperature, and chelator structure, the method achieves high specific activity (1,000-2,000 Ci/mmol) while maintaining stability throughout the F-18 half-life period, enabling both high imaging quality and practical manufacturing/distribution timelines.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables the production of F-18 labeled peptides with high specific activity and stability, reducing the need for purification steps and specialized equipment, while ensuring safety and ease of use in clinical settings, facilitating effective in-vivo imaging.
Implementation Method 1
binding F-18 to a metal
Implementation Method 2
chelating the F-18 metal complex with a ligand on the peptide
Data Source
AI summary
The present application discloses compositions and methods of synthesis and use of F-18 labeled molecules of use in PET imaging. In particular embodiments, the labeled molecules may be peptides or proteins, although other types of molecules may be labeled and utilized. Preferably, the F-18 is attached to a targeting molecule by formation of a metal complex and binding of the F-18-metal complex to a chelating moiety. In other embodiments, the metal may first be attached to the chelating group and subsequently the F-18 bound to the metal. More preferably, the F-18 label moiety may be attached to a targetable conjugate that is used for pretargeting in combination with a bispecific or multispecific antibody. The F-18-metal labeled molecules are stable in human serum at 37° C.